Maldonado-Restrepo Angela Isabel, Acelas-Gonzalez Gabriel E, Rodríguez-Vargas Gabriel-Santiago, Rodriguez-Linares Pedro, Gonzalez-Rodriguez Javier-Leonardo, Rojas-Villarraga Adriana, Santos-Moreno Pedro
School of Management and Business, Research Group Management and Business, Universidad del Rosario, Bogotá, Colombia.
Research Vicerectory, Fundación Universitaria de Ciencias de la Salud - FUCS, Bogotá, Colombia.
Clinicoecon Outcomes Res. 2025 Apr 17;17:349-373. doi: 10.2147/CEOR.S498994. eCollection 2025.
Rheumatoid arthritis (RA) affects approximately 0.3 to 1.2% of the world's population. The objective of this study was to identify the existing literature on economic evaluations of RA in Latin America.
Studies of economic evaluations of patients with RA from 2000 to 2023 were analyzed using the databases PubMed, Scopus, Web of Science, Embase, Cochrane, and the Virtual Health Library following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Study quality was assessed using the Joanna Briggs Institute (JBI) tool, and qualitative analysis was done (following SwiM guidelines).
A total of 851 articles were identified. Following the application of inclusion criteria to titles and abstracts, 117 articles were initially considered eligible. Of these, 42 were excluded due to population or outcome-based errors, leaving 27 articles and 48 abstracts for analysis. Duplicates were removed prior to this process. The included studies involved various designs: cross-sectional, longitudinal, prospective, and retrospective. Brazil accounted for the highest proportion of publications (33.3%), followed by Colombia and Mexico, each contributing 26%. Most economic studies focused on cost analysis (86%), while cost-effectiveness studies and cost-utility studies represented 7.4% and 3.3%, respectively. Predominant perspectives included third-party payer 26%, insurers 14.8%, social providers 7.4%, and mixed providers 3.7%. In terms of publications of abstracts, Colombia leaded at 35.4%. The predominant perspective was that of the provider 66.6%, including the general perspective (37.5%), private (34.3%), public (22%), and mixed (6.2%) and the perspective of third-party payers (33.3%).
Economic evaluations of rheumatoid arthritis in Latin America remain limited, with most studies focusing on cost analysis. Brazil, Colombia, and Mexico lead in publications, primarily from a provider perspective. Greater emphasis on cost-effectiveness and broader economic evaluations is needed to guide health policy in the region.
类风湿关节炎(RA)影响着全球约0.3%至1.2%的人口。本研究的目的是识别拉丁美洲有关RA经济评估的现有文献。
按照系统评价和Meta分析的首选报告项目(PRISMA)指南,使用PubMed、Scopus、科学网、Embase.com、Cochrane和虚拟健康图书馆数据库,对2000年至2023年RA患者经济评估的研究进行分析。使用乔安娜·布里格斯研究所(JBI)工具评估研究质量,并进行定性分析(遵循SwiM指南)。
共识别出851篇文章。在对标题和摘要应用纳入标准后,最初有117篇文章被认为符合条件。其中,42篇因基于人群或结果的错误被排除,剩下27篇文章和48篇摘要进行分析。在此过程之前已去除重复项。纳入的研究涉及多种设计:横断面研究、纵向研究、前瞻性研究和回顾性研究。巴西的出版物占比最高(33.3%),其次是哥伦比亚和墨西哥,各占26%。大多数经济研究侧重于成本分析(86%),而成本效益研究和成本效用研究分别占7.4%和3.3%。主要视角包括第三方支付者(26%)、保险公司(14.8%)、社会提供者(7.4%)和混合提供者(3.7%)。在摘要出版物方面,哥伦比亚领先,占35.4%。主要视角是提供者视角(66.6%),包括总体视角(37.5%)、私立(34.3%)、公立(22%)和混合(6.2%)以及第三方支付者视角(33.3%)。
拉丁美洲类风湿关节炎的经济评估仍然有限,大多数研究侧重于成本分析。巴西、哥伦比亚和墨西哥在出版物方面领先,主要是从提供者视角出发。需要更加强调成本效益和更广泛的经济评估,以指导该地区的卫生政策。